Systematic literature review and meta-analysis of B-cell therapies in systemic lupus erythematosus

Abstract

A113 platelet production, resulting in low platelet counts (thrombocytopenia). Romiplostim has shown efficacy in increasing platelet counts. The objective of this study was to conduct meta-analysis and present total evidence for Romiplostim for treatment of ITP. METHODS: For this meta-analysis we included randomized controlled trials (RCTs) evaluating Romiplostim for the treatment of ITP. We included RCTs that compared romiplostim versus placebo for management of ITP, had a treatment duration of at least 24 weeks, were doubleblind (patients and investigators blinded) and reported data on platelet response. A systematic literature search for Etanercept trials was undertaken for the databases Pubmed, Embase, Biosis, Google Scholar, and Cochrane. Data was collected for the study size, interventions, year, and the two outcomes overall and durable platelet response rate. For meta-analysis, random effects and fixed effects models were used to obtain cumulative statistics. RESULTS: Two RCTs with a total of 125 patients were identified. The pooled response rates for Romiplostim for overall platelet response rate were 82% (95% CI 73%-90%); and for durable platelet response rate were 48% (95% CI 26%-71%). The pooled response rates for placebo for overall platelet response rate were 7% (95% CI 0%-15%), and for durable platelet response rate were 2% (95% CI 0%-4%). For overall platelet response rate the cumulative relative risk with Romiplostim versus placebo was 0.09 (95% CI 4%-14%). For durable platelet response rate, the cumulative relative risk with Romiplostim versus placebo was 0.03 (95% CI 0%-6%). CONCLUSIONS: Meta-analysis shows Romiplostim offers patients with ITP an effective therapeutic option for increasing platelet counts.